John T McDevitt,
Professor, Division of Biomaterials,
New York University College of Dentistry Bioengineering Institute
John T. McDevitt now serves as a Full Professor within the Division of Biomaterials within the Department of Molecular Pathobiology at New York University, is a member of NYU’s Bioengineering Institute and participates as a distinguished faculty member in the NYU Department of Chemical and Biomolecular Engineering within the Tandon School of Engineering at NYU. Prior to this time, McDevitt served as the Chair of the Department of Biomaterials at NYU, the Brown-Weiss Professor of Bioengineering/Chemistry at Rice University, the Director of the Gulf Coast Consortium on early Disease Detection within the Texas Medical Center and a Full Professor of Chemistry and Biochemistry at University of Texas at Austin. McDevitt completed his Ph.D. degree in Chemistry from Stanford University.
Professor McDevitt is a pioneer in the development of ‘programmable bio-nano-chip’ technologies. He has a strong track record of translating essential bioscience, artificial intelligence and medical microdevice discoveries into real-world clinical practice. In this capacity, he has served as the Scientific Founder for a number of diagnostic and clinical services companies including OraLiva which features smart diagnostics for early disease detection as well as SensoDx which develops and monetizes programmable diagnostic hardware. McDevitt and his team have raised over $45M in Federal and Foundation support for academic efforts and over $50M to support commercial diagnostic activities. McDevitt and his team have process over 100 patent and patent applications. His recent research has been sponsored by major programs funded by National Institute of Dental and Craniofacial Research (NIDCR) division of the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) at NIH, Bill and Melinda Gates Foundation, Cancer Prevention Research Institute of Texas (CPRIT), NASA (National Aeronautics and Space Administration), Renaissance Health Service Corporation (Delta Dental of MI), the Army and the United Kingdom’s Home Office Scientific Development Branch.
McDevitt and his team have written more than 200 peer-reviewed scientific manuscripts and have contributed. This work was recognized with the “2020 People’s Choice Award for the TOPx COVID-19 initiative”, “2016 AACC Wallace H. Coulter Lectureship Award,” “Best of What's New Award” in the Medical Device Category by Popular Science as well as for the “Best Scientific Advances Award” by the Science Coalition. Dr. McDevitt’s individual honors include the Presidential Young Investigator Award, the California Polytechnic Distinguished Alumni Award and the Exxon Education Award. Over the past years, Dr. McDevitt has served as the Principal Investigator for 6 major clinical trials and 2 clinical pilot studies, all involving the programmable bio-nano-chip. Through these clinical efforts, mini-sensor ensembles are being developed for major diseases in the areas of COVID-19 disease severity, oral cancer, cardiac heart disease, trauma, drugs of abuse, ovarian cancer and prostate cancer.
Development and Deployment of ‘Smart Diagnostics’: Next Generation Point of Care Sensors with Capacity to Learn
Monday, 13 December 2021 at 18:00
Add to Calendar ▼2021-12-13 18:00:002021-12-13 19:00:00Europe/LondonDevelopment and Deployment of ‘Smart Diagnostics’: Next Generation Point of Care Sensors with Capacity to LearnExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
While COVID-19 has yielded devastating consequences over the past few years, the global pandemic also has opened the door for acceleration of development of core diagnostic capabilities that have the potential to lead to lasting impact for our society. With this vantage point in mind, in the recent past the McDevitt laboratory has launched a series of efforts that target the development and deployment of ‘smart diagnostics’ that serve as distributed point of care sensor nodes with capacity to learn. These mini-sensor ensembles with embedded artificial intelligence integrate programmable chip-based diagnostic systems capable of multiplexed measurements alongside clinical decision support tools that utilize strategically chosen nonclinical data elements that elicit signatures that can be used to capture diseases before they spiral out of control. As such, these efforts link for the first-time the following five key disciplines: i) lab-on-a-chip technologies, ii) in vitro diagnostics, iii) -omics research, iv) artificial intelligence, and v) digital healthcare delivery systems.
Importantly, the combination of point-of-care medical microdevices and machine learning has the potential transform the practice of medicine. In this area, scalable lab-on-a-chip devices have many advantages over standard laboratory methods including portability, faster analysis, reduced cost, lower power consumption, and higher levels of integration and automation. Despite significant advances in medical microdevice technologies over the years, several remaining obstacles are preventing clinical implementation and market penetration of these novel medical microdevices. Similarly, while machine learning has seen explosive growth in recent years and promises to shift the practice of medicine toward data-intensive and evidence-based decision making, its uptake has been hindered due to the lack of integration between clinical measurements and disease determinations.
In this talk, our recent advances in ‘smart diagnostics’ will be highlighted. These smart diagnostics include single-use microfluidic cartridges that serve as fully integrated, self-contained devices that contain aqueous buffers suitable for automated completion of all assay steps within nontraditional healthcare settings. Further, a portable analyzer instrument is fashioned to integrate fluid delivery, optical detection, image analysis, and user interface, representing a universal system for acquiring, processing, and managing clinical data while overcoming many of the challenges facing the widespread clinical adoption of lab-on-a-chip technologies. Intimate linkages between these medical microdevices and cloud connected databases allows for early disease detection algorithms to be used to impact clinical progress.
Add to Calendar ▼2021-12-13 00:00:002021-12-15 00:00:00Europe/LondonExtracellular Vesicles (EVs): Technologies and Biological InvestigationsExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2021-12-13 18:00:002021-12-13 19:00:00Europe/LondonDevelopment and Deployment of ‘Smart Diagnostics’: Next Generation Point of Care Sensors with Capacity to LearnExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
